Della Corte et al analyzed the transcriptomic and proteomic profiles in a treatment naïve and a relapsed NSCLC cohort and The Cancer Genome Atlas to identify a predictive biomarker for chemo-immunotherapy. Tumors were stratified by Stimulator of Interferon Genes (STING) pathway activation. What is the rationale for considering activation of the STING pathway as a potential biomarker for chemo-immunotherapy?